Ozempic and other GLP‑1 weight‑loss drugs face new protein‑muscle guidelines, theft surge, and trademark dispute

An international consensus on the use of GLP‑1 agonists such as Ozempic, Wegovy and Mounjaro recommends a daily protein intake of 1–1.5 g per kilogram of adjusted body weight (minimum 60 g) and the inclusion of strength‑training exercises to preserve lean muscle mass during treatment. Experts warn that rapid weight loss can lead to muscle loss, a thinner facial appearance (“Ozempic face”), and even hair shedding if nutrition is inadequate.

In Brazil, criminal groups have increasingly targeted these high‑value injectable drugs. Police operation “Efeito Colateral” seized 12 suspects, citing an 800 % rise in thefts and estimated losses of R$280 million. Pharmacies are adopting security measures such as tracking chips and restricted display of the medications.

Separately, Novo Nordisk, the maker of Ozempic, sought to block the Brazilian brand “Ozivy” registered by EMS Sigma Pharma, arguing it copies the Ozempic and Wegovy names. The Federal Regional Court (TRF‑2) rejected the request, ruling that exclusive rights do not extend to individual prefixes or suffixes and that the trademark registration remains valid.

Additional guidance from health authorities in Spain and Greece emphasizes dietary adjustments to mitigate gastrointestinal side effects of GLP‑1 drugs, underscoring that these medications treat obesity as a chronic disease and must be used under medical supervision.